Effects of Two Different Doses of Eperisone in the Treatment of Acute
Total Page：16
File Type：pdf, Size：1020Kb
Effects of Two Different Doses of Eperisone in the Treatment of Acute Low Back Pain Frandisco Colomer Rusinyol; Ramón Viladot Pericé°, Enrique Rodriguez Boronat°, Francisco Ferrer Bosch°°. Traumatology and Orthopaedic Service, Hospital Municipal de Badalona; °Traumatology and Orthopaedic Service, Clinica Tres Torres, Barcelona; °°Traumatology Service, Clinica Metalùrgica, Barcelona (Spain). Correspondence and reprint requests to: Dr. Ramón Viladot Pericé, Clinica Tres Torres, Doctor Roux Street 76, E-08017 Barcelona (Spain). Tel. 93 204 13 00; Fax 93.280 64 88; email: ctt@grup- trestorres.com KEY WORDS: eperisone, diazepam, reducing muscle contracture and impair- muscle relaxants, contracture. ment of working capacity. Conclusions: Eperisone represents a sig- ABSTRACT nificant advancement among the cen- Objectives: to evaluate efficacy and tol- trally active muscle relaxant agents both erability of two different dosages of in terms of efficacy and safety. A daily eperisone (150 and 300 mg/day) in com- dosage of 300 mg appears to be effective parison with those of diazepam 15 for management of patients with acute mg/day, orally given for seven days. painful spinal muscle contracture. Methods: Spontaneous and provoked INTRODUCTION pain, muscular contracture and its Acute low back pain (LBP) is a very impact on working capacity as well as common symptom affecting up to 90% “hand-to-floor” distance and degree of of all adults at least once in their life. lumbar tract flexion were assessed in a Most of cases are represented by an randomised double-blind trial on 90 LBP episode or a nonspecific lumbago, patients with acute muscle contractures. which is usually self-limited without any Adverse effects were also monitored. serious underlying pathology, but some- times the LBP may be the spy of an Results: Diazepam and eperisone 150 underlying severe disease, such as cauda mg/day had comparable efficacy, but the equina syndrome, cancer, infection or incidence of adverse effects and drowsi- fracture1. ness was significantly lower in Among patients with acute nonspe- eperisone— than in diazepam-treated cific mechanical LBP, the most frequent patients. Moreover, eperisone 300 pharmacological approach is the admin- mg/day was superior to diazepam in istration (or self-administration) of Vol. 9, No.1 & 2, 2009 • The Journal of Applied Research 23 paracetamol, nonsteroidal anti-inflam- of tolperisone-type centrally acting mus- matory drugs (NSAID) and skeletal cle relaxant drugs; moreover, muscle relaxants. The rationale for using tolperisone, eperisone and silperisone8 muscle relaxants is that spine muscles had also a marked effect on voltage- contraction may produce clinical disabil- gated calcium channels. These data sug- ity by interfering with posture, motor gest that eperisone and its analogues capacity, nursing or daily living activities. exert their spinal reflex inhibitory action In these cases, the distribution of muscle predominantly via a presynaptic inhibi- over-activity can be limited by the use of tion of the transmitter release from the drugs that modulate neurotransmitters primary afferent endings via a combined acting at the cortico-spinal level, such as action on voltage-gated sodium and cal- Á-aminobutyric acid (GABA), glycine, cium channels9. glutamate, noradrenaline and serotonin2. In addition, it has been reported that Sometimes, centrally acting drugs the effects of eperisone in patients with such as baclofen, tizanidine and chronic LBP could be mediated by an diazepam, could be preferred in the activity on the paraspinal muscle hemo- muscle contracture of spinal origin, dynamics with improved intramuscular whereas dantrolene sodium, due to its oxygenation during lumbar extension primarily peripheral mechanism of and flexion10. action, may be preferable in spasticity of In spite of it’s large clinical use, pub- central origin (stroke and traumatic lished evidences of the efficacy of brain injury) where sensitivity to sedat- eperisone are limited to the treatment of ing effects is generally higher3. However, patients with myelopathy or tropical most of these treatments have recently spastic paraparesis11, neurogenic been recently questioned by the bladder12, increased muscular tone after Cochrane group4; thus, an interest exists stroke13, and muscle cramps from liver for new centrally active muscle relaxant diseases14; in addition, a double-blind, agents without detrimental effects on randomized, placebo-controlled trial has the central nervous system (CNS). shown a clear benefit of eperisone on Eperisone hydrochloride is a novel pain in the nuchal region, back pain, antispastic agent, which has been devel- pain in arms and shoulders, stiffness and oped in Japan and is now marketed in other symptoms in patients with cervical Japan, India and the Far East under the spondylosis15. brand name Myonal®. It works by relax- On the contrary, there areis no con- ing both skeletal muscles and vascular trolled comparative clinical trials in the smooth muscles, thus demonstrating a treatment of patients with LBP; thus, we variety of effects such as reduction of wanted to investigate the efficacy and myotonia, improvement of circulation, the tolerability of two escalating dosages and suppression of the pain reflex. The of eperisone (150 mg and 300 mg daily), drug inhibits the vicious cycle of myoto- in comparison with those of diazepam nia by decreasing pain, ischemia and 15 mg daily. hypertonia in skeletal muscles, thus alle- viating stiffness and spasticity, and facili- MATERIALS AND METHODS tating muscle movement5-7. Ninety patients of both sexes aged over Results obtained with compounds more than 18, were selected among belonging to the same pharmacological those visiting the Orthopaedic and class, such as tolperisone, support the Traumatology Divisions of our hospitals view that blockade of sodium channels for medical advice because of LBP. may be a major component of the action Criteria for inclusion were a clinically 24 Vol. 9, No. 1 & 2, 2009 • The Journal of Applied Research Table 1. Effects of the different treatment on pain at rest and on palpation, muscular con- tracture, working capacity and “hand-to-floor” distance (see text for methods of assess- ment). Statistically significant difference: * p<0.01 vs. eperisone 50 mg t.i.d.; ° p<0.01 vs. diazepam 5 t.i.d. Day diazepam 5 mg tid Eperisone 50 mg tid Eperisone 100 mg tid Pain at rest 0 1.57 ± 0.73 1.73 ± 0.74 1.65 ± 0.63 3 1.10 ± 0.72 1.25 ± 0.65 0.91 ± 0.59* 7 0.52 ± 0.63 0.77 ± 0.71 0.36 ± 0.49* Pain at palpation 0 2.00 ± 0.64 2.07 ± 0.64 2.04 ± 0.72 3 1.34 ± 0.67 1.46 ± 0.64 1.17 ± 0.49* 7 0.79 ± 0.77 0.96 ± 0.77 0.59 ± 0.59* Muscular contracture 0 2.17 ± 0.59 1.76 ± 0.69 1.73 ± 0.53 3 1.34 ± 0.67 1.36 ± 0.62 1.00 ± 0.52*° 7 0.76 ± 0.74 0.71 ± 0.69 0.48 ± 0.60* Impaired working 0 1.90 ± 0.48 1.93 ± 0.69 1.65 ± 0.49 capacity 3 1.52 ± 0.51 1.61 ± 0.57 1.52 ± 0.59*° 7 1.31 ± 0.47 1.31 ± 0.47 1.09 ± 0.43*° Hand-to-floor 0 35.17 ± 13.44 37.43 ± 16.21 28.92 ± 13.96 distance 3 23.11 ± 14.89 27.61 ± 14.62 15.61 ± 9.82* 7 13.48 ± 13.36 18.73 ± 16.15 7.38 ± 6.37* relevant acute LBP arisen oversince less activity the investigator informed the than 48 hours, and a muscular contrac- patient about the nature and purposes ture of mild to severe intensity. Criteria of the study, and any possible risk that for exclusion were: a) history of hyper- might have occurred during the treat- sensitivity to benzodiazepines; b) any ment. Patients were also informed that anti-inflammatory and/or analgesic drug they could suspend the trial at any given in the last 24 hours; c) pregnant or moment without any justification. nursing mothers; d) disturbances of noci- According to a randomization ception and/or proprioception that could sequence, the patients were allocated to negatively affect neuronal reflexes and a double-blind oral treatment with motility; e) severe cardiovascular dis- either diazepam 5 mg three times daily eases; f) history and/or presence of any (t.i.d.) (DIA), eperisone 50 mg t.i.d. hepatic or renal disease, or other condi- (EPE150) or eperisone 100 mg t.i.d. tions which could affect the drugs’ (EPE300), for seven consecutive days. absorption and disposition; g) ongoing The investigational medicinal products infective diseases; h) chronic rheumatic were manufactured in a way to guaran- diseases; i) neoplasias of the vertebral tee the full blindness for both patients column. and investigators. According to the Helsinki The efficacy of the treatments was Declaration and the recommendations evaluated by the physicians according to of the Spanish Medical Deontological the following parameters: a) intensity of Codex (“Codigo Deontologico Medico pain in rest position and on palpation Espaniol”), before any trial-related measured by means of a 4-point scale (0 The Journal of Applied Research • Vol. 9, No. 1 & 2, 2009 25 = none; 1 = mild; 2 = moderate; 3 = test was used to confirm the homogene- severe); b) intensity of muscular contrac- ity of the variances. Afterwards, the most ture by a 5-point scale (0 = none; 1 = appropriate parametric tests (post-hoc minimum; 2 = mild; 3 = moderate; 4 = Bonferoni test) were used for normally severe); c) the impact on muscular con- distributed variables, while the non- tracture on working capacity by a 4- parametric tests were used for the other point scale (1 = no limitation of activity; variables. 2 = partial limitation, but able to per- For non- parametric tests the homo- form usual activities; 3 = not self-suffi- geneity of qualitative variables was ini- cient, needs help; 4 = bedridden).